Is Pfizer Stock a Buy After This Win?
2026-03-25 18:20:00 ET
After years of lagging the market, has Pfizer (NYSE: PFE) finally found a spark? With unimpressive financial results and recent launches that have not generated enough sales to turn things around, the pharmaceutical giant is betting that solid pipeline development could finally allow it to bounce back. And recently, the drugmaker reported results from a clinical trial that had the market buzzing, sending Pfizer's shares up by about 3% on the heels of the news. Is this the beginning of a sustained run? Let's find out whether now is a good time to invest in the stock.
Image source: Getty Images.
On March 17, Pfizer announced that an investigational candidate, atirmociclib, performed well in a phase 2 study in patients with second-line metastatic breast cancer. The medicine, when combined with another breast cancer therapy called fulvestrant -- marketed as Faslodex -- significantly improved progression-free survival versus Faslodex alone, or another combo treatment.
NASDAQ: PFE
PFE Trading
0.21% G/L:
$28.305 Last:
13,123,203 Volume:
$28.50 Open:
